Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Will Monitor Off-Label Drug Use And Report To IG Under Neurontin Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

Corporate integrity agreement will be carefully studied in pharmaceutical industry given uncertainties surrounding off-label promotion rules. Pfizer agrees to establish clear policies and keep close tabs on off-label use – but the agreement does not define prohibited or permitted activities.

Related Content

Cephalon Settles Federal Investigation Of Marketing Practices For $425 Million
Biotechs’ Size A Competitive Advantage Over Big Pharma In Compliance Arena – BIO Panel
Pfizer Faces Class Action Suit Alleging Off-Label Promotion Of Lipitor
AstraZeneca Rx Promotions Subject Of U.S. Attorney Investigation
Trileptal Off-Label Promotion Subject Of Philadelphia U.S. Attorney Subpoena
Senate Finance Committee Probes Industry Use Of Educational Grants
Pfizer Creates “More Adversarial” Government Investigations Group
Pfizer Under Investigation By New York AG Spitzer
Off-Label Promotion Remains Vulnerable To Prosecution, Justice Department Says
Paxil Suit Shows Off-Label Prosecutions By States Can Be "More Dangerous" Than Federal Cases





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts